Hamlet BioPharma
8.83 SEK
+5.12 %
Less than 1K followers
HAMLET B
Spotlight Stock Market
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
+5.12 %
+50.94 %
+49.66 %
+49.66 %
+66.60 %
+126.41 %
+148.36 %
+19.70 %
+299.10 %
Hamlet BioPharma operates in the pharmaceutical industry. The company conducts drug development based on a tumor-killing protein-lipid complex, formed from two natural and harmless molecules found in breast milk. The development aims to produce preparations that will primarily be used for the treatment and prevention of cancer diseases. Hamlet BioPharma was founded in 2015 and is headquartered in Lund.
Read moreMarket cap
1.63B SEK
Turnover
1.58M SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
22/5
2026
Interim report Q3'26
28/8
2026
Annual report '26
13/11
2026
Interim report Q1'27
All
Press releases
ShowingAll content types
Hamlet BioPharma AB (publ): Hamlet BioPharma tillförs cirka 8.5 miljoner kronor genom teckning av teckningsoptioner serie TO5B, s.k. korta optioner
Hamlet BioPharma AB (publ): Hamlet BioPharmas digital monthly investor meeting on the 18th of March
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools